Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
Information source: Department of Veterans Affairs
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Alzheimer Disease; Dementia; Dementia, Vascular; Pain
Intervention: hydrocodone/APAP (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Department of Veterans Affairs Official(s) and/or principal investigator(s): A. Lynn Snow, PhD MS BS, Principal Investigator, Affiliation: VA Medical Center, Tuscaloosa
Summary
The purpose of this study is to determine whether a low dose an opiate pain medication is
effective for the treatment of discomfort in patients with advanced dementia. The study
medication is also known as Lortab and contains both a narcotic pain medication and the same
pain medication as contained in Tylenol. The study will also assess how well patients
tolerate this medication and will measure the impact that relief of discomfort has on
agitation and other symptoms. This study is an eight-week long clinical trial for
discomfort among veterans with advanced dementia who are admitted to a Nursing Home Care
Unit (NHCU) at the Tuscaloosa VA Medical Center.
Clinical Details
Official title: Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Discomfort Battery(DB), Discomfort Scale for patient with Dementia Alzheimer's Type(DS-DAT)
Secondary outcome: Pain Assessment in Advanced Dementia (PAINAD)
Detailed description:
OBJECTIVES: The primary objective of the Low-Dose Opiate Therapy for Discomfort in Dementia
(L-DOT) project will be to determine whether low-dose opiates are effective and well
tolerated for the treatment of pain (as manifest by discomfort) in patients with advanced
dementia. The secondary objectives will be to assess the tolerability of such treatment and
to assess the impact of effective analgesia on agitation and other symptom burden in this
population.
RESEARCH DESIGN: This study is a two-week double-blind, double-dummy, placebo-controlled,
crossover trial of low-dose hydrocodone/acetaminophen (Lortab) for discomfort among veterans
with a dementia, followed by six weeks of open-label therapy for patients who tolerate
treatment during the first two weeks (eight weeks total treatment on study).
METHODOLOGY: After consent, patients over age 55 with dementia residing in a nursing home
care unit (or at home who receive care) at Tuscaloosa VAMC who demonstrate significant
discomfort (as measured by the Pain Assessment in Advanced Dementia - PAINAD) will be
randomized to one of two groups, using a double-blind, double-dummy, placebo-controlled,
crossover design. Patients will be randomly assigned to treatment with either
hydrocodone/acetaminophen 2. 5mg/250mg q8hrs scheduled with placebo q8hrs PRN or placebo
q8hrs scheduled with hydrocodone/acetaminophen 2. 5mg/250mg q8hrs PRN. After one week's
treatment, patients will be crossed over to the other (opposite) regimen, for a total of two
weeks of blinded treatment. Patients who tolerate treatment with hydrocodone/acetaminophen
will be eligible for a six-week, open-label continuation phase. Outcome measures will
include pain/discomfort, agitation, symptom burden, tolerability/adverse effects, and
dropout rates. Preliminary sample size calculations indicate that 42 patients (48 patients
accounting for dropouts) would need to be enrolled over three years to detect a difference
between treatments with power of .80 and two-tailed alpha of .05.
SIGNIFICANCE: There is evidence that pain is both under recognized and undertreated in long
term care settings. This study will make a significant contribution to the evidence base
for a common and problematic situation among veterans with advanced dementia. Advances in
pain and symptom control are central to the improvement of palliative care intervention for
dementia patients. Low-dose opiates are the logical next category of analgesics to
consider, but have not been studied for this purpose in this population.
RESULTS: Analyses are underway and expected will be completed May 2014.
Eligibility
Minimum age: 55 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 55 years of age or older;
- Must have a diagnosis of dementia;
- Advanced stage of dementia demonstrated by a score of 6 or greater on the Functional
Assessment Staging (FAST) scale;
- Unable to report pain in a reliable and consistent manner;
- Have a PAINAD score of at least 2 on two consecutive assessments (separated by at
least two days) OR an average PAINAD score of at least 2 on three consecutive
assessments each separated by at least two days;
- The patient must have at least one medical condition associated with pain recorded on
the CPRS problem list.
Exclusion Criteria:
- The existence of an effective analgesia treatment regimen;
- Pain treatment related to angina or pain judged to be related to angina;
- Current pain treatment with opiates that cannot, in the opinion of the attending
physician, be discontinued without placing the patient at risk for increased pain or
opiate withdrawal;
- Current pain treatment with tramadol that cannot, in the opinion of the attending
physician, be discontinued;
- Presence of necessary drug therapy that is incompatible with or has potential for
clinically significant drug interaction with either hydrocodone or acetaminophen;
- A history of allergy, hypersensitivity, or intolerance to either hydrocodone or
acetaminophen;
- Constipation refractory to current treatment measures or a condition that would make
constipation dangerous for the patient in the opinion of the attending physician;
- The presence of liver disease, hepatic encephalopathy, or clinically significant
elevation of liver function tests (LFTs), as determined by the attending physician;
- The presence of renal failure, clinically significant renal insufficiency, or
clinically significant elevations of serum BUN or creatinine levels, as determined by
the attending physician; OR
- Evidence, based on assessment by a geriatrician, that the apparent behavioral
manifestations of discomfort are better explained by another problem (e. g., fever,
infection, dehydration, delirium, psychosis)
Locations and Contacts
VA Medical Center, Tuscaloosa, Tuscaloosa, Alabama 35404, United States
Additional Information
Starting date: October 2007
Last updated: April 28, 2014
|